The effect of selenium supplementation on disease activity and immune-inflammatory biomarkers in patients with mild-to-moderate ulcerative colitis: a randomized, double-blind, placebo-controlled clinical trial

• Published in: European journal of nutrition 2023-12, Vol.62 (8), p.3125-3134
• Main Authors: Khazdouz, Maryam, Daryani, Naser Ebrahimi, Cheraghpour, Makan, Alborzi, Foroogh, Hasani, Motahareh, Ghavami, Shaghayegh Baradaran, Shidfar, Farzad
• Format: Article
• Language: English
• Subjects: Biomarkers; Chemistry; Chemistry and Materials Science; Clinical trials; Cytokines; Double-blind studies; Inflammatory bowel disease; Inflammatory bowel diseases; Interleukin 10; Interleukin 17; IRCT; IRCT20091114002709N51; Nutrition; Original Contribution; Patients; Placebos; Quality of life; Remission; Remission (Medicine); Selenium; Selenomethionine; Serum levels; Supplements; Ulcerative colitis
• ISSN: 1436-6207; 1436-6215
• DOI: 10.1007/s00394-023-03214-9

Purpose Selenium (Se) supplementation may help reduce inflammation and disease activity in ulcerative colitis (UC) patients. We investigated the therapeutic effects of Se administration in cases with mild-to-moderate active UC. Methods A multicenter, double-blind, randomized clinical trial (RCT) was conducted on 100 cases with active mild-to-moderate UC. The patients were randomly allocated to be given an oral selenomethionine capsule (200 mcg/day, n  = 50) or a placebo capsule ( n  = 50) for 10 weeks. The primary outcome was defined as disease activity via the Simple Clinical Colitis Activity Index (SCCAI), and secondary outcomes were measured at the end of the study. Results After 10 weeks, the SCCAI score's mean was reduced in the Se group ( P